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Abstract 
Objective: As part of the national Be Clear on Cancer campaign, the ‘blood in pee’ campaign was 
launched in 2013. We aimed to evaluate the impact of the campaign on 2-week wait (2WW) 
referrals and the resulting diagnoses of malignancy at a single trust, and secondly, to evaluate the 
socio-economic background of patients referred. 
 
Patients and methods: Suspected cancer 2WW patients in the 3 months pre- and post-campaign 
were included. Demographics, investigations and diagnoses were recorded. A Kolmogorov–Smirnov 
test demonstrated a normal distribution. The data were treated as parametric and analysed with the 
unpaired Student’s t-test. 
 
Results: Referrals for visible haematuria significantly increased by 52% from 135 pre-campaign to 
205 post-campaign (p = 0.03). There was a fall in the proportion of patients diagnosed with 
malignancy from 20.27% pre-campaign to 15.36% post-campaign. The mean index of multiple 
deprivation score of referrals did not change: p = 0.43. 
 
Conclusion: This campaign has increased referrals without increasing the proportion of malignancies 
diagnosed, placing large demand on services without benefit or extra funding. Nor has the campaign 
effectively reached deprived socioeconomic groups. There is little evidence as to the efficacy of 
untargeted cancer awareness campaigns and further work is needed to improve their pick-up of 
malignancies. 
 
Level of evidence: 2C 
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Introduction 
About a quarter of new cases of bladder cancer diagnosed are at a late stage, a concern addressed 
by NICE in their guidelines highlighting symptoms associated with bladder cancer and the 
appropriate referral pathway for patients with suspected bladder cancer.(1) 
Several public awareness studies have shown that knowledge of symptoms and risk factors for 
cancer among the general population is poor (2). It is thought that increased awareness of key 
symptoms of bladder cancer would help earlier detection and improve survival. It is estimated that 
between 5,000 to 10,000 cancer deaths within 5 years of diagnosis could be avoided each year in 
England if efforts to promote earlier diagnosis were to be successful (3). In response, the UK 
Department of Health published “Improving outcomes: A Strategy for Cancer” in 2011.  This strategy 
included public awareness campaigns designed to help people recognise symptoms of concern.  
The national “blood in pee” campaign ran from October to November 2013 and was repeated in 
2014 and 2016. The key message was: “If you notice blood in your pee, tell your doctor.” The 
advertising highlights that finding cancer earlier makes cure more likely. The campaign was aimed at 
men and women above the age of 50 from lower socio-economic groups.  This included advertising 
on television and radio, in newspapers, internet and branded pharmacy bags.  
Whilst the ‘Be clear on cancer’ campaign was  rolled out across several cancer sites, there have been 
reports that the campaign did not increase referrals from socio-economic backgrounds where 
poorer outcomes are more prevalent, and increased referral of the ‘worried well’, having no effect 
on detection rates (4)(5). 
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The aim of the present study was to evaluate impact of the campaign on service and diagnosis in a 
UK centre, and to see whether the campaign reached the targeted the socio-economic background. 
 
 
Method 
All patients referred to the Royal Derby Hospital using the suspected genitourinary tract cancer 
2WW pathway 3 months before (June 2013 to August 2013) and 3 months after (November 2013 to 
January 2014) the initial campaign were identified using the hospital’s cancer audit prospectively 
maintained database. Basic patient demographic data, clinical reason for referral, subsequent 
investigations, cost analysis and eventual diagnosis were all collected.  Patients’ postcodes were 
cross referenced with Indices of Multiple Deprivation (IMD) 2010 scores to identify socio-economic 
group of the patient (6). The stage of the tumour was also recorded if a diagnosis of bladder cancer 
was made.  Costs were obtained from the hospital’s patient level information and costing systems 
(PLICS).  The appropriateness of referrals according to NICE criteria was not assessed.   
Data Analysis 
A Kolmogorov-Smirnov test was performed on the data, demonstrating a normal distribution. The 
data were therefore treated as parametric.  Data was analysed with the unpaired t-test using 
Microsoft Excel 2013 (Microsoft, Seattle, USA).   
 
 
Results 
Pre-campaign Demographics 
Three hundred and sixty five patients were referred via the 2WW pathway in the 3 months prior to 
the launch of the national ‘blood in pee’ campaign.   The median age was 66 years (range 19-98) and 
73% were men (n=265).  The number of people above the age of 50 was 326 (89%). A total of 239 
(65%) referrals were for haematuria; both visible and non-visible (135 and 104 respectively).  Ninety-
three (25.4%) were referred because of elevated age-specific PSA and the rest were due to testicular 
lump(n=4), haematospermia (n=1), abnormal penile examination (n=11) or urinary tract infection 
with haematuria (n=7)(Table 1).  
 
Post-campaign Demographics 
Four hundred and sixty-one patients were referred via the 2WW pathway in the 3 months following 
the campaign.  The median age was unchanged from pre-campaign at 66 years (range 18-92) and 
68% were men (n=313).  The number of people above the age of 50 was 414 (90%).  A total of 327 
(70.8%) referrals were for haematuria; both visible and nonvisible (205 and 122 respectively).  One 
hundred and two patients (22.1%) were referred because of elevated age-specific PSA and 32 
patients were referred for other reasons. (Table 1). 
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The total number of referrals for all reasons increased by 26% and referrals for visible-haematuria 
increased significantly by 52% (p=0.03). NHS England data on GP referrals for suspected urinary tract 
cancer were analysed for both periods to exclude an effect of seasonal variation on referrals. No 
effect was found (p=0.12)(7). 
 
Table1. Symptoms triggering a 2WW referral for suspected urothelial cancer before and after the 
first national blood in pee campaign. 
Reason for referral 
 
Pre-campaign (n) Post-campaign (n) 
Visible haematuria 135 205 
Non-visible haematuria 104 122 
Elevated PSA 93 102 
Testicular lump 4 2 
Haematospermia 1 2 
Abnormal penile exam 11 7 
Urinary tract infection 7 1 
Other 10 20 
Total 365 461 
 
 
Socio-economic factors 
The average Index of Measures of Deprivation (IMD) 2010 score before the campaign was 17.09 
(range 3.40-65.14) while the average IMD 2010 score for patients after the campaign was 17.9 
(range 2.71-65.14). (p=0.43).  The difference between socio-economic groups was not statistically 
significant despite the specific stated intention of campaign to target people from lower socio-
economic class. 
Eventual Diagnosis 
Table2. Eventual diagnosis for all haematuria referrals (NVH and VH) 
 Pre-campaign (n) Post-campaign (n) 
Cancer 26 40 
    Bladder cancer 18 30 
    Kidney or ureteric cancer 7 10 
    Other cancer 1 0 
No cancer 214 289 
 
 
There were 18 (20.27%) patients diagnosed with bladder cancer in the 3 months before the national 
campaign.  In the 3 months following the launch, 30 (15.36%) patients were diagnosed with bladder 
cancer (p=0.31) showing a drop in proportion of cancer diagnosed. The pathological stage of these 
patients is shown in Figure 1.  In addition, 7 (5.2%) patients had a diagnosis of renal/ureteric cancer 
before campaign while 10 (4.6%) patients were diagnosed with same after the campaign.  Two 
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hundred and fourteen patients before and two hundred and eighty-nine patients after the campaign 
had no cancer diagnosed.   
Figure 1. Bladder cancer histological stage at diagnosis 
 
 
 
G = grade, T = tumour stage 
 
 
Investigations and Cost Analysis 
Figure 2 and Table 3 show the numbers of investigations performed and associated costs before and 
after the campaign for all haematuria referrals. Both numbers of investigations and costs increased 
in the period after the campaign, corresponding to the increase in referrals. £36,212 extra was spent 
on investigations after the campaign compared to before. Although the total cost increased post-
campaign the cost per cancer diagnosed dropped from £3,528 pre-campaign to £3,198 post-
campaign, however this is based on a non-significant change in number of cancers diagnosed. 
 
Figure 2.The total number of investigations performed before and after the campaign for all 
haematuria referrals (NVH and VH) 
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Flexi = flexible cystoscopy, AUS = abdominal ultrasound, US = ultrasound, MRI = magnetic resonance imaging, CT = 
computerised tomography, IVU = intravenous urogram 
 
Table3. Costs associated with investigations pre and post-campaign for all haematuria referrals (NVH 
and VH) 
Investigations 
performed 
Pre-
campaign 
(n) 
Post-
campaign 
(n) 
cost per 
investigation 
(£) 
Pre-
campaign 
total cost 
(£) 
Post-
campaign 
total cost (£) 
Flexible cystoscopy 229 320 401.44 91929.76 128460.8 
AUS 236 325 50.19 11844.84 16311.75 
US testes 2 0 50.23 100.46 0 
US prostate 10 14 313.35 3133.5 4386.9 
MRI pelvis 5 6 259.97 1299.85 1559.82 
XR 232 308 40.25 9338 12397 
CT 43 83 202.87 8723.41 16838.21 
IVU 65 103 97.64 6346.6 10056.92 
Bone scan 2 5 106.24 212.48 531.2    
Overall 91717.28 127929.6 
AUS = abdominal ultrasound, US = ultrasound, MRI = magnetic resonance imaging, CT = computered tomography, IVU = 
intravenous urogram 
 
 
Discussion 
This is the first study to report the impact of the ‘Blood in Pee’ campaign on costs to secondary care. 
It is also the first to assess the socio-economic group of those patients referred. 
We show that the Be clear on cancer “Blood in Pee” campaign significantly increased the number of 
suspected new cancer referrals with haematuria, but there was no significant change in the 
diagnosis of bladder or renal tract cancer leading to a drop in proportion of cancers diagnosed. Our 
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results show a drop in the cost per cancer diagnosed after the campaign however, as the increase in 
cancers diagnosed was not significant this may devalue this finding making it difficult to draw 
conclusions form this finding.  
 In addition, the average Index Measure of Deprivation before and after campaign for both visible 
and nonvisible haematuria remained unchanged, indicating that the campaign had no effect on its 
demographic target. Archie et al reported a 92% increase in haematuria referrals with no 
corresponding significant change in cancer diagnosis in their analysis of the impact of the campaign 
on a single trust, agreeing with our findings (8). 
These findings are in line with examination of the impact of the ‘Blood in Poo’ campaign for 
colorectal cancer, again demonstrating increased referral numbers with no change in cancer 
diagnoses and no change in the socio-economic background of those referred (4). However, Public 
Health England reported an overall  increase in cancer detection rate from pilot studies  (9), 
something not found in our data. 
The campaign met its stated objective of increasing the number of people being referred for visible 
haematuria which increased significantly by over a half. Referral for nonvisible haematuria also 
increased by a more modest 17.3%.  This increase in visible haematuria referrals would imply an 
increased awareness of the signs of urological cancer, and thus success of the mass educational 
aspect of the campaign. 
While the criteria for referral for visible haematuria are straight forward, the criteria for nonvisible 
haematuria are slightly more complex and the increase would imply an increase in primary physician 
awareness about the haematuria referral guidelines, possibly increased furthermore by exposure to 
the campaign (leaflets in the workplace, screensavers on work computers etc) rather than patients 
themselves seeking attention, non-visible haematuria not alerting patients to a problem by 
definition.   We did not however formally audit weather the patient and/or primary physician was 
aware of the campaign at time of diagnosis, which if collected may have allowed us to draw a more 
‘cause and effect’ conclusion.  
The main limitation to this study is that it represents a single centre experience, albeit with a large 
catchment population of 600,000. The Bladder cancer arm of this campaign is no longer live however 
other cancers are continuing to be targeted underneath the same campaign title of ‘Be Clear on 
Cancer’ and thus ongoing analysis of these campaigns is worthwhile.  
 
 
 
Conclusions 
In conclusion, while visible haematuria is considered a reliable predictor of underlying urological 
malignancy and while this mass media campaign did increase the number of referrals for visible 
haematuria, it failed to achieve its objective of increasing referrals from lower socio-economic 
groups and has also failed to significantly increase in the number of urothelial and renal cancers 
diagnosed. There is little evidence as to the efficacy of current untargeted cancer awareness 
campaigns and further work is needed in order to improve their pick up of undiagnosed 
malignancies. 
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